JP2001514221A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001514221A5 JP2001514221A5 JP2000508361A JP2000508361A JP2001514221A5 JP 2001514221 A5 JP2001514221 A5 JP 2001514221A5 JP 2000508361 A JP2000508361 A JP 2000508361A JP 2000508361 A JP2000508361 A JP 2000508361A JP 2001514221 A5 JP2001514221 A5 JP 2001514221A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- substituted
- carbamoyl
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 description 82
- 125000003118 aryl group Chemical group 0.000 description 17
- 125000003545 alkoxy group Chemical group 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 14
- 229910052739 hydrogen Inorganic materials 0.000 description 14
- 125000001072 heteroaryl group Chemical group 0.000 description 13
- 229910052799 carbon Inorganic materials 0.000 description 12
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 10
- 150000003839 salts Chemical group 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 description 8
- 102100022339 Integrin alpha-L Human genes 0.000 description 7
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 6
- 125000000623 heterocyclic group Chemical group 0.000 description 6
- 0 CB(*(C)[C@](*)(CC(*)CC1OC(*)=O)[C@]1[C@]1C*)[C@@]1C#C Chemical compound CB(*(C)[C@](*)(CC(*)CC1OC(*)=O)[C@]1[C@]1C*)[C@@]1C#C 0.000 description 4
- 125000002947 alkylene group Chemical group 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 3
- 208000030090 Acute Disease Diseases 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 3
- 206010063837 Reperfusion injury Diseases 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- -1 carbamoyl-methyl Chemical group 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 208000037976 chronic inflammation Diseases 0.000 description 3
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- 101100341510 Mus musculus Itgal gene Proteins 0.000 description 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000005115 alkyl carbamoyl group Chemical group 0.000 description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- VEPTXBCIDSFGBF-UHFFFAOYSA-M tetrabutylazanium;fluoride;trihydrate Chemical compound O.O.O.[F-].CCCC[N+](CCCC)(CCCC)CCCC VEPTXBCIDSFGBF-UHFFFAOYSA-M 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- XJRIDJAGAYGJCK-UHFFFAOYSA-N (1-acetyl-5-bromoindol-3-yl) acetate Chemical compound C1=C(Br)C=C2C(OC(=O)C)=CN(C(C)=O)C2=C1 XJRIDJAGAYGJCK-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9718157.2A GB9718157D0 (en) | 1997-08-28 | 1997-08-28 | Organic compounds |
| GB9718157.2 | 1997-08-28 | ||
| GBGB9806413.2A GB9806413D0 (en) | 1998-03-25 | 1998-03-25 | Organic compounds |
| GB9806413.2 | 1998-03-25 | ||
| PCT/EP1998/005415 WO1999011258A1 (en) | 1997-08-28 | 1998-08-26 | Lymphocyte function antigen-1 antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2001514221A JP2001514221A (ja) | 2001-09-11 |
| JP2001514221A5 true JP2001514221A5 (https=) | 2006-01-05 |
| JP4340386B2 JP4340386B2 (ja) | 2009-10-07 |
Family
ID=26312132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000508361A Expired - Fee Related JP4340386B2 (ja) | 1997-08-28 | 1998-08-26 | リンパ球機能抗原−１アンタゴニスト |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US6630492B1 (https=) |
| EP (1) | EP1007033B1 (https=) |
| JP (1) | JP4340386B2 (https=) |
| AR (1) | AR013445A1 (https=) |
| AT (1) | ATE392894T1 (https=) |
| AU (1) | AU737735B2 (https=) |
| CO (1) | CO4970739A1 (https=) |
| DE (1) | DE69839399T2 (https=) |
| ES (1) | ES2306482T3 (https=) |
| NZ (1) | NZ502872A (https=) |
| PE (1) | PE108399A1 (https=) |
| PT (1) | PT1007033E (https=) |
| WO (1) | WO1999011258A1 (https=) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6867203B2 (en) | 1998-12-29 | 2005-03-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds |
| US6110922A (en) | 1998-12-29 | 2000-08-29 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds |
| US6878700B1 (en) | 1998-12-29 | 2005-04-12 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds |
| CO5140104A1 (es) * | 1999-02-16 | 2002-03-22 | Novartis Ag | Derivados de mevinolina y preparacion farmaceuticas que los contienen |
| WO2001007044A1 (en) | 1999-07-21 | 2001-02-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | Small molecules useful in the treatment of inflammatory disease |
| JP3833532B2 (ja) | 1999-07-21 | 2006-10-11 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 炎症性疾患の治療において有用な小分子 |
| WO2001007052A1 (en) | 1999-07-21 | 2001-02-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | Small molecules useful in the treatment of inflammatory disease |
| US6492408B1 (en) | 1999-07-21 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Small molecules useful in the treatment of inflammatory disease |
| US6573385B1 (en) | 1999-11-11 | 2003-06-03 | Biocon India Limited | Process for manufacturing simvastatin and novel intermediates thereof |
| AU2127500A (en) | 1999-11-11 | 2001-06-06 | Biocon India Limited | Process for manufacturing simvastatin and the novel intermediates |
| US6521619B2 (en) | 2000-06-29 | 2003-02-18 | Icos Corporation | Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents |
| EP1294704A1 (en) | 2000-06-29 | 2003-03-26 | Abbott Laboratories | Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents |
| DK1471054T3 (da) * | 2002-01-11 | 2009-11-09 | Daiichi Sankyo Co Ltd | Aminoalkohol-derivat eller phosphonsyre-derivat og medicinsk sammensætning, der indeholder disse |
| US6603022B1 (en) | 2002-05-10 | 2003-08-05 | Biocon India Limited | Process for manufacturing Simvastatin and novel intermediates thereof |
| EP1539744A4 (en) | 2002-07-11 | 2007-06-06 | Vicuron Pharm Inc | N-HYDROXYAMIDE DERIVATIVES WITH ANTIBACTERIAL EFFECT |
| WO2004032861A2 (en) | 2002-10-11 | 2004-04-22 | Bristol-Myers Squibb Company | Hexahydro-benzimidazolone compounds useful as anti-inflammatory agents |
| CA2544678C (en) | 2003-11-05 | 2013-12-31 | Sunesis Pharmaceuticals, Inc. | Modulators of cellular adhesion |
| WO2005066150A1 (en) * | 2004-01-02 | 2005-07-21 | Hetero Drugs Limited | A novel process for the preparation of simvastatin |
| WO2005069741A2 (en) * | 2004-01-21 | 2005-08-04 | Jubilant Organosys Limited | Process for producing simvastatin using novel hydrazide intermediates |
| NZ549162A (en) | 2004-02-24 | 2009-12-24 | Sankyo Co | Amino-pyrrol alcohol compounds |
| TW200616634A (en) | 2004-10-01 | 2006-06-01 | Bristol Myers Squibb Co | Crystalline forms and process for preparing spiro-hydantoin compounds |
| US7186727B2 (en) | 2004-12-14 | 2007-03-06 | Bristol-Myers Squibb Company | Pyridyl-substituted spiro-hydantoin compounds and use thereof |
| US7265248B1 (en) | 2005-04-29 | 2007-09-04 | Technology Innovations, Llc | Compositions and methods for the treatment of malaria |
| DK2444079T3 (en) | 2005-05-17 | 2017-01-30 | Sarcode Bioscience Inc | Compositions and Methods for the Treatment of Eye Diseases |
| GB0520378D0 (en) * | 2005-10-06 | 2005-11-16 | Novartis Ag | Organic compounds |
| EP2024341B1 (en) | 2006-05-03 | 2015-12-02 | MSN Laboratories Private Limited | Novel process for statins and its pharmaceutically acceptable salts thereof |
| US8404841B2 (en) | 2006-10-09 | 2013-03-26 | Msn Laboratories Limited | Process for the preparation of statins and their pharmaceutically acceptable salts thereof |
| ES2830024T3 (es) | 2007-10-19 | 2021-06-02 | Novartis Ag | Composiciones y métodos para el tratamiento del edema macular |
| MX2010004995A (es) | 2007-11-29 | 2010-05-20 | Boehringer Ingelheim Int | Derivados de amidas del acido 6,7-dihidro-5h-imidazo[1,2-a]imidazo l-3-carboxilico. |
| WO2009128934A1 (en) | 2008-04-15 | 2009-10-22 | Sarcode Corporation | Topical lfa-1 antagonists for use in localized treatment of immune related disorders |
| WO2010089770A2 (en) | 2009-01-19 | 2010-08-12 | Msn Laboratories Limited | Improved process for the preparation of highly pure (3r,5s)-7-[2-cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxy-6(e)-heptenoic acid and pharmaceutically acceptable salts thereof |
| EP2241561A1 (en) * | 2009-04-16 | 2010-10-20 | Neuron Biopharma, S.A. | Neuroprotective, hypocholesterolemic and antiepileptic compound |
| WO2010141330A1 (en) | 2009-06-02 | 2010-12-09 | Boehringer Ingelheim International Gmbh | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES |
| BRPI1012581A2 (pt) | 2009-06-02 | 2016-03-29 | Boehringer Ingelheim Int | derivados de amidas de ácido 6, 7-di-hidro-5h-imidazol[1,2-a]imidazol-3-carboxílico |
| US8987444B2 (en) | 2010-01-18 | 2015-03-24 | Msn Laboratories Private Limited | Process for the preparation of amide intermediates and their use thereof |
| ES2380473B1 (es) * | 2010-10-13 | 2013-02-19 | Neuron Biopharma, S.A. | Compuesto neuroprotector, hipocolesterolémico, antiinflamatorio y antiepiléptico. |
| WO2014012054A1 (en) * | 2012-07-13 | 2014-01-16 | Pain Therapeutics, Inc. | Alzheimer's disease assay in a living patent |
| ES2524647B1 (es) | 2013-06-06 | 2015-09-15 | Neuron Bio, S.A. | Compuestos neuroprotectores, antiinflamatorios y antiepilépticos |
| US20190038588A1 (en) * | 2016-02-11 | 2019-02-07 | Stichting Katholieke Universiteit | Novel class of compounds for the treatment of cardiovascular disease |
| WO2018106945A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| US20200253506A1 (en) | 2016-12-14 | 2020-08-13 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
| US20230033021A1 (en) | 2018-06-20 | 2023-02-02 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
| EP3883635A1 (en) | 2018-11-19 | 2021-09-29 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
| CN115666704B (zh) | 2019-12-13 | 2025-09-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1193906B (it) | 1980-01-31 | 1988-08-31 | Acna | Coloranti dispersi-reattivi adatti alla tintura ed alla stampa delle fibre miste poliestere-cellulosa |
| PT72394B (en) * | 1980-02-04 | 1982-09-06 | Merck & Co Inc | Process for preparing dihydro and tetrahydromevinoline hypocholesterolimics |
| US4611081A (en) * | 1985-07-05 | 1986-09-09 | Merck & Co., Inc. | Process for the preparation of HMG-CoA reductase inhibitors intermediates |
| US4665091A (en) | 1985-11-04 | 1987-05-12 | Merck & Co., Inc. | Macrocyclic lactone HMG-CoA reductase inhibitors |
| US4876366A (en) | 1986-05-05 | 1989-10-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
| EP0245003A3 (en) | 1986-05-05 | 1989-07-19 | Merck & Co. Inc. | Antihypercholesterolemic compounds |
| US5116870A (en) * | 1986-06-23 | 1992-05-26 | Merck & Co., Inc. | HMG-CoA reductase inhibitors |
| US4678806A (en) | 1986-09-02 | 1987-07-07 | Merck & Co., Inc. | Prodrugs of antihypercholesterolemic compounds |
| US5075327A (en) * | 1988-08-10 | 1991-12-24 | Hoffmann-La Roche Inc. | Antipsoriatic agents |
| US5072002A (en) | 1989-07-18 | 1991-12-10 | The Governors Of The University Of Alberta | Synthesis of cholesterol-lowering agents |
| US5620876A (en) * | 1992-04-29 | 1997-04-15 | E. R. Squibb & Sons, Inc. | Enzymatic hydrolysis and esterification processes for the preparation of HMG-CoA reductase inhibitors and intermediates thereof |
| NZ250609A (en) * | 1992-12-28 | 1995-07-26 | Sankyo Co | Hexahydronaphthalene esters and ring closed lactones; preparation and medicaments |
| US6355664B1 (en) | 1997-03-03 | 2002-03-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | Phenylpyrrolidines, phenylimidazolidines, 3-phenyl-1,3-oxizolidines and 3-phenyl-1,3-thiazolidines and their use in the treatment of inflammatory disease |
-
1998
- 1998-08-26 NZ NZ502872A patent/NZ502872A/xx unknown
- 1998-08-26 JP JP2000508361A patent/JP4340386B2/ja not_active Expired - Fee Related
- 1998-08-26 US US09/486,244 patent/US6630492B1/en not_active Expired - Fee Related
- 1998-08-26 ES ES98951317T patent/ES2306482T3/es not_active Expired - Lifetime
- 1998-08-26 AR ARP980104257A patent/AR013445A1/es unknown
- 1998-08-26 EP EP98951317A patent/EP1007033B1/en not_active Expired - Lifetime
- 1998-08-26 AU AU97391/98A patent/AU737735B2/en not_active Ceased
- 1998-08-26 WO PCT/EP1998/005415 patent/WO1999011258A1/en not_active Ceased
- 1998-08-26 PT PT98951317T patent/PT1007033E/pt unknown
- 1998-08-26 AT AT98951317T patent/ATE392894T1/de not_active IP Right Cessation
- 1998-08-26 DE DE69839399T patent/DE69839399T2/de not_active Expired - Lifetime
- 1998-08-27 PE PE1998000798A patent/PE108399A1/es not_active Application Discontinuation
- 1998-08-28 CO CO98049375A patent/CO4970739A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001514221A5 (https=) | ||
| EP0184550B1 (de) | 5-Amino-4-hydroxyvalerylamid-Derivate | |
| DE69127970T2 (de) | Immunosuppressive verbindungen | |
| KR102483876B1 (ko) | 아미노 피리미딘 ssao 억제제 | |
| EP0719253B1 (en) | 3-amino-5-carboxy-substituted piperidines and 3-amino-4-carboxy-substituted pyrrolidines as tachykinin antagonists | |
| CN1133637C (zh) | 雷公藤内酯类似物及其组合物和应用 | |
| JP5805763B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| US6630492B1 (en) | Lymphocyte function antigen-1 antagonists | |
| EA022384B1 (ru) | Ингибиторы вируса гепатита c | |
| RU2069662C1 (ru) | Производные пиразоло [1,5-а] пиридина, или их фармацевтически приемлемые соли и способ их получения | |
| JP2020528062A (ja) | ピペラジンヘテロアリール誘導体、その製造方法、およびその医薬での使用 | |
| EP0733642A1 (de) | Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäure-derivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| EP0532466A2 (de) | 5-Amino-4-Hydroxyhexansäurederivate als Therapeutika | |
| EP4265605A1 (en) | Fibroblast activation protein inhibitor | |
| CA3116198A1 (en) | Compounds containing deuterium | |
| US7915303B2 (en) | Glycopyrronium salts and their therapeutic use | |
| DE69610792T2 (de) | Inhibitoren mit zweifacher Wirkung, die 1,2-Diazepin enthalten | |
| US20020037895A1 (en) | Mevinolin derivatives | |
| EP0374098A2 (de) | Retrovirale Proteasehemmer | |
| CA2070972A1 (en) | Cyclic renin inhibitors | |
| KR102335082B1 (ko) | 헤테로사이클릭 화합물 및 이의 용도 | |
| KR920002141B1 (ko) | 이합체 에피포도필로톡신 글루코사이드 유도체 | |
| JPH06228132A (ja) | 抗レトロウイルス性アシル化合物 | |
| CA2070983A1 (en) | Cyclic renin inhibitors | |
| CN103570806A (zh) | 多肽环氧酮化合物 |